Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIN1 | Q13526 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.45 |
| ▸ | PLG | P00747 | 1/20 | 0.45 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.45 |
| ▸ | PRSS2 | P07478 | 1/20 | 0.45 |
| ▸ | PRSS3 | P35030 | 1/20 | 0.45 |
| ▸ | TPSAB1 | Q15661 | 1/20 | 0.45 |
| ▸ | FOLH1 | Q04609 | 9/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.43 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.38 |
| ▸ | RAMP3 | O60896 | 5/20 | 0.38 |
| ▸ | CALCR | P30988 | 5/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20705971 | 0.92 | PIN1 (0.48) | PIN1F2PLGPRSS1PRSS2 | |
| SCHEMBL22803360 | 0.81 | PRSS1 (0.52) | PIN1F2PLGPRSS1PRSS2 | |
| SCHEMBL30128547 | 0.76 | PLG (0.47) | PIN1F2PLGPRSS1PRSS2 | |
| SCHEMBL6176082 | 0.75 | RAMP3 (0.54) | RAMP3CALCR | |
| SCHEMBL26585156 | 0.74 | TDP1 (0.56) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL7113668 | 0.73 | FOLH1 (0.50) | PIN1F2PLGPRSS1PRSS2 | |
| SCHEMBL31378126 | 0.73 | TDP1 (0.66) | FOLH1TDP1CAPN1 | |
| SCHEMBL24067574 | 0.73 | TDP1 (0.55) | F2PRSS1PRSS2PRSS3TPSAB1 | |
| SCHEMBL6176075 | 0.73 | RAMP3 (0.52) | RAMP3CALCR | |
| SCHEMBL22803169 | 0.72 | NRP1 (0.45) | RAMP3CALCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | KLEO PHARMACEUTICALS, INC. | 2020-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200390895-A1 | UNIVERSAL ABT COMPOUNDS AND USES THEREOF | CD47, MCL1, BCL9 | PIN1 1869/4885F2 3188/4885PLG 1135/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.